Clinical efficacy of Jiedu Huayu Hushen prescription in treatment of acute－on－chronic liver failure complicated by hepatorenal syndrome

Yanjie LI; Sha WANG; Na WANG; Zhanjin MO; Dewen MAO; Qinglan SHI; Zuhong HUANG; Wenjie BO; Fuli LONG; Kun TANG; Peipei FENG; Min YANG

doi:10.3969/j.issn.1001-5256.2023.09.018

Volume 39 Issue 9

Sep. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(9): 2151-2157

PDF( 693 KB)

Clinical efficacy of Jiedu Huayu Hushen prescription in treatment of acute－on－chronic liver failure complicated by hepatorenal syndrome

DOI: 10.3969/j.issn.1001-5256.2023.09.018

1.
Department of Liver Diseases，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China
2.
Guangxi University of Chinese Medicine，Nanning 530022，China

Research funding:

Guangxi Natural Science Foundation Innovation Team Project (2018GXNFSFGA281002);

Guangxi Science and Technology Base and Talent Specialization Project (Guike AD17129001);

State Administration of Traditional Chinese Medicine Fifth National Training Program for Outstanding Clinical Talents in Traditional Chinese Medicine (National TCM Human Education Letter ［2022］ No. 1);

The Basic Ability Enhancement Program for Young and Middle－aged Teachers of Guangxi (2022KY0284);

Guangxi Natural Science Foundation of China (2020GXNSFAA297070);

Guangxi Chinese Medicine Appropriate Technolgy Development and Promotion Program (GZSY21－12)

More Information

Corresponding author: SHI Qinglan， bshiqinglan@163.com （ORCID： 0000－0002－6454－3309）
Received Date: 2022-12-12
Accepted Date: 2023-01-12
Published Date: 2023-09-19

Abstract

Abstract

Objective To investigate the clinical efficacy of Jiedu Huayu Hushen prescription in the treatment of acute－on－chronic liver failure （ACLF） complicated by hepatorenal syndrome （HRS） and its effect on endotoxemia. Methods Clinical data were collected from 96 patients with ACLF complicated by HRS who were diagnosed and treated in The First Affiliated Hospital of Guangxi University of Chinese Medicine from March 2020 to June 2022， and they were divided into observation group and control group using a random number table， with 48 patients in each group. In addition to comprehensive Western medicine therapy， the patients in the control group were given norepinephrine and albumin， while those in the observation group were given Jiedu Huayu Hushen prescription combined with norepinephrine and albumin， and the course of treatment was 2 weeks for both groups. The two groups were compared in terms of serum endotoxin level， traditional Chinese medicine （TCM） syndrome score， 24－hour urine volume， renal function， liver function， coagulation function， and clinical outcome. The independent－samples t test was used for comparison of continuous data between two groups， paired t－test was used for comparison before and after treatment within the group； and the chi－square test was used for comparison of categorical data between two groups. Results Compared with the control group after 2 weeks of treatment， the observation group had a significantly lower TCM syndromes core （P<0.05）， significantly lower levels of endotoxin， blood urea nitrogen， serum creatinine， cystatin C， and prothrombin time （all P<0.05）， and significantly higher levels of glomerular filtration rate， 24－hour urine volume， serum albumin， and prothrombin time activity （all P<0.05）. After 2 weeks of treatment， the observation group had a significantly higher overall response rate than the control group （87.50% vs 66.67%， P<0.05）. Conclusion Based on comprehensive Western medicine therapy， Jiedu Huayu Hushen prescription can reduce serum endotoxin level， improve liver and renal function and coagulation function， and increase urine volume in patients with ACLF complicated by HRS， with a better clinical efficacy than Western medicine therapy alone.
- Acute－On－Chronic Liver Failure,
- Hepatorenal Syndrome,
- Jiedu Huayu Hushen Prescription,
- Endotoxemia

FullText(HTML)

References(13)

References

[1]	SHI QL, WU JY, MAO DW, et al. Study on the effect of Jiedu Huayu formula II on immune reconstitution in patients with chronic acute liver failure[J]. Tradit Chin Drug Res Clin Pharmacol, 2022, 33( 3): 392－ 397. DOI: 10.19378/j.issn.1003－9783.2022.03.017. 石清兰, 吴金玉, 毛德文, 等. 解毒化瘀Ⅱ方对慢加急性肝衰竭患者免疫重建的影响[J]. 中药新药与临床药理, 2022, 33( 3): 392－ 397. DOI: 10.19378/j.issn.1003－9783.2022.03.017.
[2]	LYU C, MAO DW, QIN Q, et al. Effect of Wenyang Huayu Tuihuang Decoction in the treatment of hepatitis B－related chronic and acute liver failure[J]. China Med Her, 2019, 16( 30): 142－ 146. 吕超, 毛德文, 覃倩, 等. 温阳化瘀退黄方治疗乙型肝炎相关慢加急性肝衰竭的效果[J]. 中国医药导报, 2019, 16( 30): 142－ 146.
[3]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007.
[4]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408－ 2425. DOI: 10.3969/j.issn.1001－5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408－ 2425. DOI: 10.3969/j.issn.1001－5256.2019.11.006.
[5]	LIU MY, YE YA. Thinking after diagnosis and treatment of a patient with hepatorenal syndrome[J]. Clin J Tradit Chin Med, 2011, 23( 4): 344－ 345. DOI: 10.16448/j.cjtcm.2011.04.036. 刘梦阳, 叶永安. 1例肝肾综合征患者诊治后的思考[J]. 中医药临床杂志, 2011, 23( 4): 344－ 345. DOI: 10.16448/j.cjtcm.2011.04.036.
[6]	HUANG ZM, HUANG RF, TANG Y, et al. Effects of Sanqi injection on inflammatory initiators and terminators in rats model with adriamycin－induced renal fibrosis[J]. Chin Arch Tradit Chin Med, 2021, 39( 5): 175－ 178. DOI: 10.13193/j.issn.1673－7717.2021.05.042. 黄志敏, 黄仁发, 唐宇, 等. 三七注射液对阿霉素肾纤维化大鼠炎症启动因子和终止因子的影响[J]. 中华中医药学刊, 2021, 39( 5): 175－ 178. DOI: 10.13193/j.issn.1673－7717.2021.05.042.
[7]	AI LM, DU GS, JIANG FC. Prevention of severe hepatitis hepatorenal syndrome by benzylamine oxazoline Salvia miltiorrhiza and rhubarb[J]. Chin J Integr Tradit West Med Liver Dis, 1991, 1( 2): 33－ 34. 艾黎明, 杜功舜, 蒋方才. 苄胺唑啉丹参及大黄预防重症肝炎肝肾综合症[J]. 中西医结合肝病杂志, 1991, 1( 2): 33－ 34.
[8]	HE HY, LI H, YANG Y, et al. The protective effects of fructus canarii and puerariae combination treatment on alcohol－induced rat liver injury[J]. J Med Theory Pract, 2015, 28( 12): 1541－ 1543. DOI: 10.19381/j.issn.1001－7585.2015.12.001. 何鸿雁, 李华, 杨艳, 等. 青果葛根配伍液对醉酒大鼠肝脏损伤的保护作用研究[J]. 医学理论与实践, 2015, 28( 12): 1541－ 1543. DOI: 10.19381/j.issn.1001－7585.2015.12.001.
[9]	SUN WC, ZHOU HP. Clinical observation of puerarin combined with western medicine in treatment of chronic ischemic nephropathy[J]. Hubei J Tradit Chin Med, 2017, 39( 12): 6－ 8. 孙文才, 周和平. 葛根素联合西医常规治疗慢性缺血性肾病的临床观察[J]. 湖北中医杂志, 2017, 39( 12): 6－ 8.
[10]	LI X, LIU XY, LI BX, et al. Discussion on hepatorenal syndrome from Guan Ge[J]. Lishizhen Med Mater Med Res, 2019, 30( 9): 2214－ 2216. DOI: 10.3969/j.issn.1008－0805.2019.09.056. 李霞, 刘西洋, 李白雪, 等. 从关格论肝肾综合征[J]. 时珍国医国药, 2019, 30( 9): 2214－ 2216. DOI: 10.3969/j.issn.1008－0805.2019.09.056.
[11]	YI GD, TAN J. Protective effects of schisandrin B on rat model of hepatorenal syndrome and its possible mechanism[J]. J Med Res, 2018, 47( 9): 172－ 175. DOI: 10.11969/j.issn.1673－548X.2018.09.041. 易国栋, 谭静. 五味子乙素对肝肾综合征大鼠的保护作用及其机制研究[J]. 医学研究杂志, 2018, 47( 9): 172－ 175. DOI: 10.11969/j.issn.1673－548X.2018.09.041.
[12]	ZHAO ZL, KANG HY, ZHANG Z, et al. Clinical observation of Danhong injection combined with terlipressin in the treatment of severe hepatitis complicated with type 2 hepatorenal syndrome[J]. Mod J Integr Tradit Chin West Med, 2018, 27( 15): 1637－ 1640. DOI: 10.3969/j.issn.1008－8849.2018.15.012. 赵子龙, 康海燕, 张志, 等. 丹红注射液联合特利加压素治疗重型肝炎合并2型肝肾综合征疗效观察[J]. 现代中西医结合杂志, 2018, 27( 15): 1637－ 1640. DOI: 10.3969/j.issn.1008－8849.2018.15.012.
[13]	LEI XQ, WEI HY, TAN RZ, et al. Effects of Huangqi Sanqi Mixture on cisplatin－induced acute kidney injury in mice[J]. Chin Tradit Pat Med, 2022, 44( 4): 1107－ 1113. DOI: 10.3969/j.issn.1001－1528.2022.04.012. 雷小琴, 魏何燕, 谭睿陟, 等. 黄芪三七合剂对顺铂诱导小鼠急性肾损伤的影响[J]. 中成药, 2022, 44( 4): 1107－ 1113. DOI: 10.3969/j.issn.1001－1528.2022.04.012.

Relative Articles

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 王宪波，时克，冯颖. 慢加急性肝衰竭早期预警及中西医结合治疗特色优势. 中国中西医结合消化杂志. 2024(03): 189-194 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(8)

Get Citation

PDF

XML

Article Metrics

Article views (477) PDF downloads(25)

Clinical efficacy of Jiedu Huayu Hushen prescription in treatment of acute－on－chronic liver failure complicated by hepatorenal syndrome

DOI: 10.3969/j.issn.1001-5256.2023.09.018

Abstract

References

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical efficacy of Jiedu Huayu Hushen prescription in treatment of acute－on－chronic liver failure complicated by hepatorenal syndrome

DOI: 10.3969/j.issn.1001-5256.2023.09.018

Abstract

References

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content